Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: marks (231), results (1000)

G29 Guideline on completion application and study assessment v1 14-10-20...

Description: Guideline on completion of the Sponsorship Application and Study Assessment Introduction According to the UK Policy Framework for Health and Social
Url: /Media/Southampton-Clinical-Research/Downloads/G29-Guideline-on-completion-application-and-study-assessment-v1-14-10-20....pdf

Nordic 3000

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-CYTARABINE-DOXORUBICIN-PREDNISOLONE-RITUXIMABVINCRISTINE (Nordic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nordic-3000.pdf

Nordic_2000

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-CYTARABINE-DOXORUBICIN-PREDNISOLONE-RITUXIMABVINCRISTINE (Nordic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nordic-2000.pdf

VenetoclaxHigh

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (high risk) Regimen • CLL – Venetoclax (high risk) Indication • Venetoclax is indicated for the treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxHigh.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen • CLL – VR Rituximab Venetoclax (high
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf

cancer-genetics-referral-guidelines

Description: Wessex Clinical Genetics Service, G Level, Mailpoint 627, Princess Anne Hospital, Coxford Road, Southampton SO16 5YA Tel: 023 8120 6170 https
Url: /Media/UHS-website-2019/Docs/Services/Genetics/Cancer-genetics/cancer-genetics-referral-guidelines2.docx

Carboplatin (AUC4.5) Gemcitabine

Description: Chemotherapy Protocol BLADDER CARBOPLATIN (AUC4.5)-GEMCITABINE Regimen  Bladder-Carboplatin-Gemcitabine Indication  Locally advanced or metastatic urothelial cancer  WHO performance status
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Carboplatin-AUC4.5-Gemcitabine.pdf

Carboplatin (AUC6) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN Retreat Regimen (AUC6) • Ovary – Carboplatin (AUC6) Retreat Indication • Second line or subsequent treatment of platinum sensitive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC6Retreat.pdf

Asciminib

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Asciminib Regimen • Asciminib Indication • Patients with chronic phase Philadelphia chromosome-positive chronic myeloid Leukaemia previously treated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Asciminib.pdf

CarboplatinAUC4-Gemcitabine (1)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC4)-GEMCITABINE (day 1) Regimen • Ovary-Carboplatin (AUC4)-Gemcitabine (1) Indication • Recurrent platinum sensitive ovarian cancer
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC4-Gemcitabine1.pdf

391 to 400 of 548

Previous … 38 39 40 41 42 … Next